Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.55 |
| ▸ | HTR3B | O95264 | 4/20 | 0.55 |
| ▸ | HTR3A | P46098 | 4/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937735 | 1.00 | ADRB1 (0.59) | ADRB1HTR6MAOBPLD1HTR3E | |
| Hydrochloric Acid SCHEMBL3185751 | 0.98 | HTR6 (0.59) | ADRB1HTR6MAOBPLD1HTR3E | |
| Hydrochloric Acid SCHEMBL31061057 | 0.98 | HTR6 (0.59) | ADRB1HTR6MAOBPLD1HTR3E | |
| SCHEMBL24615261 | 0.83 | HRH4 (0.47) | ADRB1HTR6MAOBCYP1A2HTR7 | |
| SCHEMBL29157425 | 0.82 | DYRK1A (0.61) | ADRB1DYRK1ANMT1 | |
| SCHEMBL19027125 | 0.81 | HRH4 (0.54) | TP53CYP1A2HTR7HTTALDH1A1 | |
| SCHEMBL19288501 | 0.79 | ADRB1 (0.59) | ADRB1HTR6MAOBPLD1ADRB2 | |
| SCHEMBL22581914 | 0.79 | ADRB1 (0.64) | ADRB1HTR6MAOBPLD1ADRB2 | |
| SCHEMBL3848354 | 0.79 | ADRB1 (0.59) | ADRB1HTR6MAOBPLD1ADRB2 | |
| SCHEMBL1026043 | 0.79 | ADRB1 (0.59) | ADRB1PLD1NCF1HRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3200589-B1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12269809-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-08 | — | — | US | disclosed |
| US-20220306596-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-09-29 | — | — | US | disclosed |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-05-05 | — | — | US | disclosed |
| US-11192871-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200223810-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-07-16 | — | — | US | disclosed |
| US-10544117-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | disclosed |
| US-20170298037-A1 | Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3200589-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | Temple University Of The Commonwealth System Of Higher Education (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016183150-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016040554-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-03-17 | — | — | WO | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2013066729-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ADRB1 4339/4885HTR6 4707/4885MAOB 3848/4885 |
| US-11192871-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | ADRB1 79/4885HTR6 3/4885MAOB 62/4885 |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | ADRB1 14/4885HTR6 99/4885MAOB 552/4885 |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | ADRB1 16/4885HTR6 77/4885MAOB 326/4885 |
| US-20170298037-A1 | Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use | HTR7, HTR6, HTR5A | ADRB1 95/4885HTR6 2/4885MAOB 87/4885 |
| US-20200223810-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | ADRB1 95/4885HTR6 2/4885MAOB 87/4885 |
| US-10544117-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | ADRB1 73/4885HTR6 3/4885MAOB 44/4885 |
| US-20220306596-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | ADRB1 95/4885HTR6 2/4885MAOB 87/4885 |
| US-12269809-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | ADRB1 79/4885HTR6 3/4885MAOB 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.